Merrimack Pharmaceuticals takes a technological approach to fighting cancer. A biopharmaceutical company, Merrimack develops oncology drugs using its proprietary Network Biology technology, which combines biological data and computer-based modeling to discover and develop candidates. In 2015, it received US approval and Taiwan approval of ONIVYDE for the treatment of pancreatic cancer, but it sold that drug to Ipsen in 2017. The firm then owned three key programs, but two of those failed in mid-stage testing. A year after slashing its workforce by 80%, it announced plans to cut another 60% of its staff in 2018. Merrimack traces its roots back to the early 1990s.
See detailed business credit reports on other businesses or your own.
See detailed profiles for insights and prospects on this company's top competitors.
Essential information for a successful call
EMPLOYEES (All Sites)
- ASSETS (MIL USD) 20
REVENUE (MIL USD)
- TICKER SYMBOL MACK
- Incorporated 1993
- FISCAL YEAR END DEC
Get in Touch with 126 Contacts and 5 Principals*
Gary CrockerChairman of the Board
GARY L CROCKERChairman of the Board
JEAN M FRANCHIChief Financial Officer and Treasurer
JEFFREY A MUNSIEGeneral Counsel and Secretary